arm GlaxoSmithKline Pharmaceuticals for a total consideration of Rs 6,389.02 crore.
The penchant for multinationals to take over Indian firms was clearly indicated when US pharma major Mylan Inc decided to acquire Agila Specialties, maker of generic injectable products, from Bangalore-based Strides Arcolab Ltd for USD 1.6 billion (about Rs 8,700 crore).
In a case highlighting uncertain nature of international collaborations, Dr Reddy's Laboratories and Fujifilm Corporation decided to terminate a pact to establish a joint venture and an exclusive partnership for generic drugs business in the Japanese market.
2013 will also go down in the history of Indian pharma industry when landmark decisions were made. The Supreme Court rejected plea of Swiss pharma giant Novartis, for a patent on cancer drug Glivec paving way for Indian generic firms to offer cheaper alternatives.
Ending a seven-year legal battle, the apex court dismissed the company's plea and held that there was no new invention and no new substance used in the drug.
The development raised questions over India's patent regime from multi nationals but the government stood firm and said Indian laws were WTO compliant and no country could allow "ever-greening" of patents.
In another blow to foreign pharma companies, the Intellectual Property Appellate Board (IPAB) ordered the revocation of the patent given to GSK Pharma's popular breast cancer drug, Tykerb.
In view of the developments, Swiss pharma major Roche Holding AG said it won't pursue the secondary patent for its breast cancer drug 'Herceptin' in India.
On the other hand, the government rejected a compulsory licensing application by BDR Pharmaceuticals to manufacture the generic version of patented anti-cancer drug 'Dasatinib', a decision that is seen as evidence that IP rules prevail in India.
Commenting on the developments, Novartis India Vice Chairman and Managing Director Ranjit Shahani told PTI: "As far as the innovator Pharma Companies were concerned they continue to face challenges on implementation of patents and threat of more compulsory licenses."
While most of the domestic industry welcomed India's stand on the patents, in an interview to PTI, Biocon Chairman and Managing Director Kiran Mazumdar-Shaw said that India needs to show the world that it respects intellectual property rights